Biohaven (NYSE:BHVN) Raised to “Sell” at Wall Street Zen

Biohaven (NYSE:BHVN) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday.

Other research analysts have also issued research reports about the company. TD Cowen lifted their price target on Biohaven from $15.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Biohaven in a report on Monday, December 29th. Morgan Stanley reduced their price target on Biohaven from $26.00 to $21.00 and set an “overweight” rating on the stock in a report on Tuesday, January 6th. Canaccord Genuity Group assumed coverage on Biohaven in a report on Monday, April 13th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Leerink Partners reiterated an “outperform” rating and set a $15.00 price target on shares of Biohaven in a report on Tuesday, March 3rd. Three investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.53.

Biohaven Trading Up 0.1%

Shares of BHVN stock opened at $11.00 on Friday. Biohaven has a fifty-two week low of $7.48 and a fifty-two week high of $24.06. The company has a debt-to-equity ratio of 4.59, a quick ratio of 3.18 and a current ratio of 3.18. The stock’s fifty day moving average is $10.22 and its two-hundred day moving average is $11.45. The firm has a market capitalization of $1.65 billion, a P/E ratio of -1.58 and a beta of 1.34.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($1.21) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.01. Research analysts expect that Biohaven will post -8.9 earnings per share for the current fiscal year.

Institutional Trading of Biohaven

Several institutional investors and hedge funds have recently bought and sold shares of the stock. ARS Investment Partners LLC raised its holdings in Biohaven by 11.2% in the 1st quarter. ARS Investment Partners LLC now owns 1,378,828 shares of the company’s stock valued at $11,665,000 after buying an additional 139,228 shares during the period. Hsbc Holdings PLC purchased a new stake in Biohaven in the 4th quarter valued at about $282,000. Caitong International Asset Management Co. Ltd purchased a new stake in Biohaven in the 4th quarter valued at about $81,000. Invesco Ltd. raised its holdings in Biohaven by 59.0% in the 4th quarter. Invesco Ltd. now owns 194,751 shares of the company’s stock valued at $2,199,000 after buying an additional 72,230 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Biohaven in the 4th quarter valued at about $342,000. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.